课题基金 / 基金详情

Preclinical Therapeutics Core

Preclinical Therapeutics Core
临床前治疗核心
批准号:
9974491
负责人:
Michael David Levin
金额:
$39.94万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-07-08 至 2024-06-30
关键词:
AgreementAnalytical ChemistryAnimal ExperimentsAnimal ModelAnimal TestingAnimalsAntibodiesAntibody FormationAntibody-drug conjugatesBiological AssayBiologyBlood VesselsCaliforniaCalorimetryCaveolaeChelating AgentsChemistryClinicalClinical TrialsCollaborationsConsultationsContractsCyclic GMPDevelopmentDextransDisease modelDoctor of PhilosophyEnsureEnzymatic BiochemistryEquipmentExclusionFluorescenceFluorescence PolarizationHybridomasHydrophobic InteractionsImageImmunoconjugatesIndustrializationInstitutionIon-Exchange Chromatography ProcedureLeadLifeLigandsLung NeoplasmsLung diseasesMass Spectrum AnalysisMedicineMethodsMolecular WeightMonoclonal AntibodiesMusNuclear Magnetic ResonancePharmaceutical PreparationsPharmacologic SubstancePhasePlatinumPreparationProceduresProcessProductionPropertyProtocols documentationQuality ControlRadioRadioactive IodineRadioactive metalRadioisotopesReagentRecombinant ProteinsRefractive IndicesReproducibilityResearchResearch ActivityResearch InstituteResearch Project GrantsResearch SupportResourcesServicesSolid NeoplasmSpectrophotometrySpectroscopy, Fourier Transform InfraredSurface Plasmon ResonanceSynthesis ChemistrySystemTechnical ExpertiseTechnologyTechnology TransferTestingTherapeuticTherapeutic AgentsTherapeutic antibodiesTimeTrainingUniversitiesValidationYangantibody conjugateantibody engineeringcGMP productionchemotherapyclinical imagingclinical translationdetectorexperienceexperimental studyhumanized antibodyimaging agentinstrumentlight scatteringmembernovelpre-clinicalprotein expressionproteogenomicsscale uptargeted imagingtherapeutic evaluationtumor

项目摘要

项目成果

Michael David Levin的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
CORE B PROJECT SUMMARY Core B Preclinical Therapeutics will provide purified antibodies for conjugation and use in Projects 1 and 2 to generate novel caveolae-targeting imaging and therapeutic agents. The Core will also provide analytical services to ensure quality control of reagents that will be used for preclinical animal testing. Antibodies generated in Core B will be conjugated to radionuclides in Core D for use in Project 1. Antibodies will be provided to Project 2 for conjugation to various chemotherapies, and testing in preclinical metastatic models of disease. Reagents developed in Projects 1 and 2 will be rigorously evaluated for quality control using analytical services provided by Core B prior to use in any animal studies. Core B will also provide support services and guidance for the cGMP production of the humanized antibody and therapeutic agents destined for clinical trials, including scale-up, process development, validation, batch testing, compliance, and providing technical expertise as needed to ensure successful technology transfer and quality manufacturing of finished goods.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Preclinical Therapeutics Core
Preclinical Therapeutics Core
Preclinical Therapeutics Core
Caveolae-Targeted Cisplatin Immunoconjugates for Effective Lung Cancer Therapy
  • 批准号:
    9408697
  • 项目类别:
  • 资助金额:
    $30.0万
  • 财政年份:
    2017
  • 负责人:
    Michael David Levin
  • 依托单位:
海外基金